{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:06:41Z","timestamp":1792033601020,"version":"4.4.0"},"reference-count":28,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Venetoclax (Ven) combined with a hypomethylating agent (HMA) has now emerged as an effective treatment regimen for acute myeloid leukemia, in both de novo and relapsed\/refractory setting. The current multicenter study retrospectively examined Ven\u2009+\u2009HMA treatment outcome among 32 patients (median age 69\u2009years; 59% males) with blast\u2010phase myeloproliferative neoplasm (MPN\u2010BP). Pre\u2010leukemic phenotype included essential thrombocythemia (ET)\/post\u2010ET myelofibrosis (34%), polycythemia vera (PV)\/post\u2010PV myelofibrosis (38%) and primary myelofibrosis (28%). Twenty\u2010nine study patients were fully annotated cytogenetically and molecularly (NGS): 69% harbored complex karyotype and\/or mutations, including\n                    <jats:italic>TP53<\/jats:italic>\n                    (41%),\n                    <jats:italic>IDH1\/2<\/jats:italic>\n                    (21%),\n                    <jats:italic>ASXL1<\/jats:italic>\n                    (21%),\n                    <jats:italic>N\/KRAS<\/jats:italic>\n                    (14%),\n                    <jats:italic>SRSF2<\/jats:italic>\n                    (10%),\n                    <jats:italic>EZH2<\/jats:italic>\n                    (10%) and\n                    <jats:italic>U2AF1<\/jats:italic>\n                    (7%). All patients received Ven combined with either azacitidine (\n                    <jats:italic>n<\/jats:italic>\n                    =\u200912) or decitabine (\n                    <jats:italic>n<\/jats:italic>\n                    =\u200920); either up front (\n                    <jats:italic>n<\/jats:italic>\n                    =\u200923) or after failing another induction therapy (\n                    <jats:italic>n<\/jats:italic>\n                    =\u20099). Complete remission with (CR) or without (CRi) count recovery was achieved in 14 (44%) patients and was more likely to occur in the absence of pre\u2010leukemic PV\/post\u2010PV myelofibrosis phenotype (\n                    <jats:italic>p<\/jats:italic>\n                    &lt;\u2009.01), complex karyotype (\n                    <jats:italic>p<\/jats:italic>\n                    &lt;\u2009.01) or\n                    <jats:italic>K\/NRAS<\/jats:italic>\n                    (\n                    <jats:italic>p<\/jats:italic>\n                    =\u2009.03) mutations; seven of eight patients (88%) without vs four of 21 (19%) with complex karyotype or\n                    <jats:italic>K\/NRAS<\/jats:italic>\n                    mutation achieved CR\/CRi (\n                    <jats:italic>p<\/jats:italic>\n                    &lt;\u2009.01); all 11 informative patients with pre\u2010leukemic PV\/post\u2010PV myelofibrosis phenotype displayed complex karyotype (\n                    <jats:italic>p<\/jats:italic>\n                    &lt;\u2009.01). In contrast, neither\n                    <jats:italic>TP53<\/jats:italic>\n                    (\n                    <jats:italic>p<\/jats:italic>\n                    =\u2009.45) nor\n                    <jats:italic>IDH1\/2<\/jats:italic>\n                    (\n                    <jats:italic>p<\/jats:italic>\n                    =\u2009.63) mutations affected response. Compared to historical controls treated with HMA alone (\n                    <jats:italic>n<\/jats:italic>\n                    =\u200926), the CR\/CRi rate (44% vs 4%) and median survival (8 vs 5.5 months) were more favorable with Ven\u2009+\u2009HMA, but without significant difference in overall survival. Importantly, six patients with CR\/CRi subsequently received allogeneic hematopoietic stem cell transplant (AHSCT). Note, Ven\u2009+\u2009HMA produces robust CR\/CRi rates in MPN\u2010BP, especially in the absence of\n                    <jats:italic>RAS<\/jats:italic>\n                    mutations and complex karyotype, thus enabling AHSCT, in some patients.\n                  <\/jats:p>","DOI":"10.1002\/ajh.26186","type":"journal-article","created":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T16:49:19Z","timestamp":1618246159000},"page":"781-789","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Venetoclax with azacitidine or decitabine in blast\u2010phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases"],"prefix":"10.1002","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-6172","authenticated-orcid":false,"given":"Naseema","family":"Gangat","sequence":"first","affiliation":[{"name":"Division of Hematology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1809-284X","authenticated-orcid":false,"given":"Paola","family":"Guglielmelli","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi University of Florence  Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Szuber","sequence":"additional","affiliation":[{"name":"Department of Hematology Universit\u00e9 de Montr\u00e9al  Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2730-8593","authenticated-orcid":false,"given":"Kebede H.","family":"Begna","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6998-662X","authenticated-orcid":false,"given":"Mrinal M.","family":"Patnaik","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9816-6302","authenticated-orcid":false,"given":"Mark R.","family":"Litzow","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aref","family":"Al\u2010Kali","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Foran","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic  Jacksonville Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne M.","family":"Palmer","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic  Scottsdale Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Alkhateeb","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7366-9886","authenticated-orcid":false,"given":"Michelle A.","family":"Elliott","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis A.","family":"Hanson","sequence":"additional","affiliation":[{"name":"Division of Hematopathology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9084-4148","authenticated-orcid":false,"given":"Animesh","family":"Pardanani","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4810-6501","authenticated-orcid":false,"given":"Francesco","family":"Mannelli","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi University of Florence  Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5755-0730","authenticated-orcid":false,"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi University of Florence  Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4605-3821","authenticated-orcid":false,"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,5,6]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2018.08.022"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0019-y"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26112"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2015.06.001"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018019661"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0778-0"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25369"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00388-x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25978"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26039"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30210-6"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25000"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106456"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17084"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2018.08.002"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2017.05.010"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.09.017"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.10.027"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002119"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.036"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002175"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003988"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018015875"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1407792111"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26122"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26061"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.26186","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.26186","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.26186","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T00:56:56Z","timestamp":1693097816000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.26186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,6]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1002\/ajh.26186"],"URL":"https:\/\/doi.org\/10.1002\/ajh.26186","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,6]]},"assertion":[{"value":"2021-03-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}